中国病理生理杂志
中國病理生理雜誌
중국병리생리잡지
CHINESE JOURNAL OF PATHOPHYSIOLOGY
2014年
12期
2128-2134
,共7页
丁浩%沈志高%李昊%邱宇%郝晓宁%祖金池%钟理
丁浩%瀋誌高%李昊%邱宇%郝曉寧%祖金池%鐘理
정호%침지고%리호%구우%학효저%조금지%종리
肺肿瘤%血浆%组织%甲基化
肺腫瘤%血漿%組織%甲基化
폐종류%혈장%조직%갑기화
Lung neoplasms%Plasma%Tissues%Methylation
目的:探究血浆中CDH13、RASSF13A、DLEC13、SEPT13、RUNX13等抑癌基因启动子甲基化及其联合检测在肺癌诊断中的价值。从中选出诊断效能高的组合。方法:采用巢式甲基化特异性PCR( nest methylation specific PCR,nMSP)法,检测106例健康人血浆样本、106例肺癌组织和癌旁组织以及其对应的106例术前血浆样本、中基因启动子区的甲基化状态。对血浆基因组DNA修饰后进行多重置换扩增( multiple displacement amplifica-tion, MDA),以解决血浆DNA模板不足的问题。结果:肺癌组织样本中的CDH13、RASSF13A、DLEC13、SEPT13、RUNX13基因启动子甲基化率分别为51.9%、44.3%、54.7%、36.8%、24.5%。对应的血浆样本中的 CDH13、RASSF1A、DLEC1、SEPT9、RUNX3基因启动子甲基化率分别为46.2%、41.5%、50.9%、31.1%、19.8%。 Kappa一致性检验结果表明肺癌组织与血浆的甲基化检出率一致。 CDH13、DLEC1、RASSF1A、SEPT9组合对肺癌的诊断效能明显高于其它组,准确度ACC为82.08%, Youden指数为0.6415(灵敏度为79.49%,特异度为81.13%)。结论:血浆多基因联合甲基化检测有望应用于肺癌早期诊断。
目的:探究血漿中CDH13、RASSF13A、DLEC13、SEPT13、RUNX13等抑癌基因啟動子甲基化及其聯閤檢測在肺癌診斷中的價值。從中選齣診斷效能高的組閤。方法:採用巢式甲基化特異性PCR( nest methylation specific PCR,nMSP)法,檢測106例健康人血漿樣本、106例肺癌組織和癌徬組織以及其對應的106例術前血漿樣本、中基因啟動子區的甲基化狀態。對血漿基因組DNA脩飾後進行多重置換擴增( multiple displacement amplifica-tion, MDA),以解決血漿DNA模闆不足的問題。結果:肺癌組織樣本中的CDH13、RASSF13A、DLEC13、SEPT13、RUNX13基因啟動子甲基化率分彆為51.9%、44.3%、54.7%、36.8%、24.5%。對應的血漿樣本中的 CDH13、RASSF1A、DLEC1、SEPT9、RUNX3基因啟動子甲基化率分彆為46.2%、41.5%、50.9%、31.1%、19.8%。 Kappa一緻性檢驗結果錶明肺癌組織與血漿的甲基化檢齣率一緻。 CDH13、DLEC1、RASSF1A、SEPT9組閤對肺癌的診斷效能明顯高于其它組,準確度ACC為82.08%, Youden指數為0.6415(靈敏度為79.49%,特異度為81.13%)。結論:血漿多基因聯閤甲基化檢測有望應用于肺癌早期診斷。
목적:탐구혈장중CDH13、RASSF13A、DLEC13、SEPT13、RUNX13등억암기인계동자갑기화급기연합검측재폐암진단중적개치。종중선출진단효능고적조합。방법:채용소식갑기화특이성PCR( nest methylation specific PCR,nMSP)법,검측106례건강인혈장양본、106례폐암조직화암방조직이급기대응적106례술전혈장양본、중기인계동자구적갑기화상태。대혈장기인조DNA수식후진행다중치환확증( multiple displacement amplifica-tion, MDA),이해결혈장DNA모판불족적문제。결과:폐암조직양본중적CDH13、RASSF13A、DLEC13、SEPT13、RUNX13기인계동자갑기화솔분별위51.9%、44.3%、54.7%、36.8%、24.5%。대응적혈장양본중적 CDH13、RASSF1A、DLEC1、SEPT9、RUNX3기인계동자갑기화솔분별위46.2%、41.5%、50.9%、31.1%、19.8%。 Kappa일치성검험결과표명폐암조직여혈장적갑기화검출솔일치。 CDH13、DLEC1、RASSF1A、SEPT9조합대폐암적진단효능명현고우기타조,준학도ACC위82.08%, Youden지수위0.6415(령민도위79.49%,특이도위81.13%)。결론:혈장다기인연합갑기화검측유망응용우폐암조기진단。
[ ABSTRACT] AIM: To determine the aberrant methylation status in the gene promoter regions of CDH13, RASSF1A, DLEC1, SEPT9 and RUNX3 by detecting the plasma specimens and the value of their combined detection for di-agnosis of lung cancers.METHODS:Nest methylation specific PCR ( nMSP) was used to detect the promoter methylation status of the 5 genes in the plasma from 106 normal controls, lung cancer tissues, lung benign tissues and the plasma from 106 patients with lung cancers.Multiple displacement amplification ( MDA) was used to amplify modified genomic DNA to solve the problem of insufficient of plasma DNA template.RESULTS: The positive rates of promoter methylation of CDH13, RASSF1A, DLEC1, SEPT9 and RUNX3 in the lung cancer tissues were 51.9%, 44.3%, 54.7%, 36.8%, 24.5%, respectively, and those in the plasma were 46.2%, 41.5%, 50.9%, 31.1%, 19.8%, respectively.The re-sults of the Kappa consistency check showed that the lung cancer tissues and the plasma had obviously coherence in the methylation status of the 5 gene promoter regions.Combination of DLEC1, CDH13, RASSF1A, and SEPT9 had a higher di-agnostic efficiency than the others, as their ACC value was 0.8208 and youden index was 0.6415 ( with the sensitivity of 81.13% and the specificity of 83.02%) .CONCLUSION:Combination detection of promoter methylation of lung cancer-related genes in the plasma is expected to apply to the early diagnosis of lung cancer.